Mononuclear arene ruthenium complexes containing 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-triazine as chelating ligand: Synthesis and molecular structure by Therrien, Bruno et al.
Published in Inorganica Chimica Acta 361, issues 9-10, 2601-2608, 2007
which should be used for any reference to this work
1Mononuclear arene ruthenium complexes containing
5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-triazine as chelating ligand:
Synthesis and molecular structure
Bruno Therrien *, Cynthia Saı¨d-Mohamed, Georg Su¨ss-Fink
Institut de Chimie, Universite´ de Neuchaˆtel, Case postale 158, CH-2009 Neuchaˆtel, SwitzerlandAbstract
The mononuclear cations of the general formula [(g6-arene)RuCl(pdpt)]+ (pdpt = 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-triazine; are-
ne = C6H6 (1); C6H5Me (2); p-Pr
iC6H4Me (3); C6Me6 (4)) have been synthesised from 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-triazine (pdpt)
and the corresponding chloro complexes [(g6-C6H6)Ru(l-Cl)Cl]2, [(g
6-C6H5Me)Ru(l-Cl)Cl]2, [(g
6p-PriC6H4Me)Ru(l-Cl)Cl]2 and [(g
6-
C6Me6)Ru(l-Cl)Cl]2, respectively. The X-ray crystal structure analyses of [1][PF6]  (C6H6)2.5 and [2][PF6]  (CH3CN)2 reveal a typical
piano-stool geometry around the metal centre and in the crystal packing a complexed networks of intermolecular interactions.
Keywords: Arene ligands; N ligand; Polypyridyl ligand; RutheniumN
N1. Introduction
Ruthenium complexes attract more and more attention
in view of their applications as biological active species
[1]. Two ruthenium-based anticancer drugs, NAMI-A [2]
and KP1019 [3], have completed phase I clinical trials and
are scheduled to enter phase II in the near future (see
Fig. 1). Among classical ruthenium anticancer drugs, poly-
pyridyl–Ru systems have been used as molecular DNA
probes owing to their photoluminescence properties and
ability to intercalate DNA [4]. These potential DNA-target-
ing anticancer agents have been screened for anticancer
activity. Numerous examples of polypyridyl–Ru complexes
including [2,20-bipyridine, 1,10-phenanthroline, 2,20:60200-
terpyridine] have been studied [5]. In all cases, their bio-
logical activity was related to their ability to intercalate
DNA.* Corresponding author. Tel.: +41 032 7182499; fax: +41 032 7182511.
E-mail address: bruno.therrien@unine.ch (B. Therrien).Similarly, organometallic g6-arene ruthenium com-
plexes have been investigated as anticancer drug candi-
dates. They are known to interact with DNA to form
monofunctional DNA adducts [4c,6]. Therefore, we were
interested in combining an arene ruthenium moiety with
a polypyridyl ligand able to interact with DNA at its
periphery. Herein we report on the synthesis and character-
isation of mononuclear arene ruthenium complexes with
the polypyridyl chelate ligand, 5,6-diphenyl-3-(pyridine-2-
yl)-1,2,4-triazine (pdpt). After coordination to the ruthe-
nium atom, the pdpt ligand still possesses a free pyridyl
function for intermolecular interactions.N
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Fig. 1. Clinically evaluated ruthenium-based anticancer drugs.
22. Experimental
2.1. General remarks
5,6-Diphenyl-3-(pyridine-2-yl)-1,2,4-triazine (pdpt) an
KPF6 were purchased from Aldrich and used as received
[(g6-arene)Ru(l-Cl)Cl]2 (arene = C6H6, C6H5Me, p
PriC6H4Me, C6Me6) were prepared according to the pub
lished methods [7]. The NMR spectra were recorded on
Bruker AMX 400 MHz spectrometer using the residua
protonated solvent as internal standard. Infrared spectr
were recorded as KBr pellets on a Perkin–Elmer FTIR
1720-X spectrometer. UV–Vis absorption spectra wer
recorded on an Uvikon 930 spectrophotometer. Microana
yses were performed by the Laboratory of Pharmaceutica
Chemistry, University of Geneva (Switzerland). Electro
spray mass spectra were obtained in positive-ion mode wit
an LCQ Finnigan mass spectrometer.
2.2. [(g6-C6H6)RuCl(pdpt)][PF6] ([1][PF6])
[(g6-C6H6)Ru(l-Cl)Cl]2 (100 mg, 0.20 mmol), pdp
(124 mg, 0.40 mmol) and KPF6 (73.6 mg, 0.40 mmol) ar
dissolved in methanol (30 mL). The mixture is heated t
50 Cand stirred for 4 h.After cooling to room temperature
the volume is reduced and the product is precipitated by th
addition of diethylether. The orange solid is ﬁltered, washe
with n-pentane and dried under vacuum to give [(g6
C6H6)RuCl(pdpt)][PF6] (60 mg, 0.09 mmol, yield 22%).
1H
NMR (400 MHz, CD3CN): d (ppm) = 6.14 (s, 6H, C6H6
7.53 (m, 4H, C6H5), 7.63 (m, 2H, C6H5), 7.75 (m, 4H
C6H5), 7.89 (dd, 1H,
3J = 5.6 Hz, C5H4N), 8.31 (dd, 1H
3J = 7.8 Hz, C5H4N), 8.68 (d, 1H,
3J = 10 Hz, C5H4N
9.52 (d, 1H, 3J = 7.6 Hz, C5H4N); IR (KBr, cm
1): m(P-F
840s; 558m. UV–Vis (6.6  105 M, CH3CN): kma
298 nm (e = 0.97  104 M1 cm1); ESI-MS (m/z): 52
[M+]; Anal. Calc. for C26H20N4ClF6PRu: C, 46.61; H
3.01; N, 8.36. Found: C, 46.60; H, 3.61; N, 8.05%.
2.3. [(g6-C6H5Me)RuCl(pdpt)][PF6] ([2][PF6])
[(g6-C6H5Me)Ru(l-Cl)Cl]2 (100 mg, 0.19 mmol), pdp
(117.5 mg, 0.38 mmol) and KPF6 (69.7 mg, 0.38 mmoare dissolved in methanol (30 mL). The mixture is heate
to 50 C and stirred for 4 h. After cooling to room temper
ature, the volume is reduced and the product is precipitate
by the addition of diethylether. The orange–brown solid
ﬁltered, washed with n-pentane and dried under vacuum t
give [(g6-C6H5Me)RuCl(pdpt)][PF6] (170 mg, 0.25 mmo
yield 66%). 1H NMR (400 MHz, CD3CN):
(ppm) = 2.34 (s, 3H, C6H5CH3), 5.79 (d, 1H,
3J = 6.0 Hz
C6H5CH3), 5.83 (d, 1H, C6H5CH3), 5.85 (dd, 1H
3J = 5.9 Hz, C6H5CH3), 6.13 (dd, 1H, C6H5CH3), 6.1
(dd, 1H, C6H5CH3), 7.46 (m, 6H, C6H5), 7.72 (m, 4H
C6H5), 7.88 (dd, 1H,
3J = 5.6 Hz, C5H4N), 8.30 (dd, 1H
3J = 7.8 Hz, C5H4N), 8.68 (d, 1H,
3J = 9.4 Hz, C5H4N
9.45 (d, 1H, 3J = 7.6 Hz, C5H4N); IR (KBr, cm
1): m(P
F) 838s; 558m; UV–Vis (5.9  106 M, CH3CN): kma
298 nm (e = 9.76  104 M1 cm1); ESI-MS (m/z): 53
[M+]; Anal. Calc. for C27H22N4ClF6PRu: C, 47.41; H
3.24; N, 8.19. Found: C, 47.19; H, 3.37; N, 8.37%.
2.4. [(g6-p-PriC6H4Me)RuCl(pdpt)][PF6] ([3][PF6])
[(g6-p-PriC6H4Me)Ru(l-Cl)Cl]2 (100 mg, 0.16 mmol
C20H14N4 (101.34 mg, 0.32 mmol) and KPF6 (60.15 mg
0.32 mmol) are dissolved in methanol (30 mL). The mix
ture is heated to 50 C and stirred for 4 h. After coolin
to room temperature, the volume is reduced and the prod
uct is precipitated by the addition of diethylether. Th
brown solid is ﬁltered, washed with n-pentane and drie
under vacuum to give [(g6-p-PriC6H4Me)RuCl(pdpt)][PF
(120 mg, 0.16 mmol, yield 51%). 1H NMR (400 MHz
CD3CN): d (ppm) = 1.20 (d, 3H,
3J = 3.4 Hz, CH(CH3)2
1.22 (d, 3H, 3J = 3.5 Hz, CH(CH3)2), 2.17 (s, 3H, CH3
2.89 (sept, 1H, 3J = 6.9 Hz, CH(CH3)2), 5.80 (d, 1H
3J = 6.2 Hz, C6H4), 5.85 (d, 1H,
3J = 6.3 Hz, C6H4), 6.0
(d, 1H, C6H4), 6.03 (d, 1H, C6H4), 7.52 (dd, 2H, C6H5
7.55 (dd, 2H, C6H5), 7.65 (m, 2H, C6H5), 7.75 (m, 4H
C6H5), 7.91 (dd, 1H,
3J = 5.6 Hz, C5H4N), 8.31 (dd, 1H
3J = 7.9 Hz, C5H4N), 8.69 (d, 1H,
3J = 10 Hz, C5H4N
9.44 (d, 1H, 3J = 7.5 Hz, C5H4N); IR (KBr, cm
1): m(P
F) 839s; 558m; UV–Vis (1.0  105 M, CH3CN): kma
300 nm (e = 3.29  104 M1 cm1); ESI-MS (m/z): 58
[M+]; Anal. Calc. for C30H28N4ClF6PRu: C, 49.63; H
3.89; N, 7.72. Found: C, 49.19; H, 3.91; N, 7.69%.
2.5. [(g6-C6Me6)RuCl(pdpt)][PF6] ([4][PF6])
[(g6-C6Me6)Ru(l-Cl)Cl]2 (100 mg, 0.15 mmol
C20H14N4 (92.8 mg, 0.30 mmol) and KPF6 (55.10 mg
0.30 mmol) are dissolved in methanol (30 mL). The mix
ture is heated to 50 C and stirred for 4 h. After coolin
to room temperature, the volume is reduced and the prod
uct is precipitated by the addition of diethylether. The dar
red solid is ﬁltered, washed with n-pentane and dried unde
vacuum to give [(g6-C6Me6)RuCl(pdpt)][PF6] (120 mg
0.16 mmol, yield 53%). 1H NMR (400 MHz, CD3CN):
(ppm) = 2.19 (s, 18H, C6(CH3)6), 7.44 (dd, 2H
3J = 7.9 Hz, C6H5), 7.54 (m, 6H, C6H5), 7.73 (d, 2H
Table 1
Crystallographic and selected experimental data for [1][PF6]  (C6H6)2.5
and [2][PF6]  (CH3CN)2
[1][PF6]  (C6H6)2.5 [2][PF6]  (CH3CN)2
Chemical formula C41H35ClF6N4PRu C31H28ClF6N6PRu
Formula weight 865.22 766.08
Crystal system monoclinic monoclinic
Space group P21/n (No. 14) P21/n (No. 14)
Crystal colour and shape red block red needle
Crystal size 0.18  0.14  0.13 0.32  0.08  0.07
a (A˚) 15.716(1) 8.5006(5)
b (A˚) 10.8734(6) 20.086(2)
c (A˚) 22.995(2) 18.890(1)
b () 98.695(6) 124.652(6)
V (A˚3) 3884.3(5) 3199.1(4)
Z 4 4
T (K) 173(2) 173(2)
Dcalc (g cm
3) 1.480 1.591
l (mm1) 0.578 0.691
Scan range () 1.70 < h < 25.66 1.49 < h < 25.66
Unique reﬂections 7311 5585
Observed reﬂections
[I > 2r(I)]
4805 3836
Rint 0.0730 0.2008
Final R indices [I > 2r(I)]a 0.0433, wR2 0.0944 0.1196, wR2 0.3046
R indices (all data) 0.0774, wR2 0.1022 0.1547, wR2 0.3202
Goodness-of-ﬁt 0.903 1.144
Maximum, minimum Dq/e
(A˚3)
0.877, 0.601 2.296, 2.387
a Structure was reﬁned on F 2o: wR2 ¼ ½
P½wðF 2o  F 2cÞ2=
P
wðF 2oÞ21=2,
where w1 ¼ ½PðF 2oÞ þ ðaPÞ2 þ bP  and P ¼ ½maxðF 20; 0Þ þ 2F 2c =3.
3C6H5), 7.93 (dd, 1H,
3J = 5.6 Hz, C5H4N), 8.26 (dd, 1H,
3J = 7.8 Hz, C5H4N), 8.68 (d, 1H,
3J = 10 Hz, C5H4N),
9.03 (d, 1H, 3J = 7.6 Hz, C5H4N); IR (KBr, cm
1): m(P-
F) 840s; 558m; UV–Vis (1.1  105 M, CH3CN): kmax
439 nm (e = 0.45  104 M1 cm1), 295 nm (e = 1.63 
104 M1 cm1); ESI-MS (m/z): 609 [M+]; Anal. Calc. for
C32H32N4ClF6PRu: C, 50.97; H, 4.28; N, 7.43. Found: C,
50.71; H, 4.40; N, 7.47%.Scheme 1. Synthesis2.6. X-ray crystallographic study
Crystals of [1][PF6]  (C6H6)2.5 are obtained by the slow
evaporation of a chloroform/benzene solution of [1][PF6],
while the crystals of [2][PF6]  (CH3CN)2 are obtained by
the slow evaporation of an acetonitrile solution of
[2][PF6]. The data were measured using a Bruker SMART
CCD diﬀractometer, using Mo Ka graphite monochromat-
ed radiation (k = 0.71073 A˚). The structures were solved by
direct methods using the program SHELXS-97 [8]. The reﬁne-
ment and all further calculations were carried out using
SHELXL-97 [8]. The H-atoms were included in calculated
positions and treated as riding atoms using the SHELXL
default parameters. The non-H atoms were reﬁned aniso-
tropically, using weighted full-matrix least-square on F2.
Crystallographic details are summarised in Table 1. Figs.
3 and 4 are drawn with ORTEP [9] and Figs. 5–7 with MER-
CURY [10].
3. Results and discussion
The arene ruthenium complexes [(g6-arene)Ru(l-Cl)Cl]2
(arene = C6H6, C6H5Me, p-Pr
iC6H4Me, C6Me6) react with
two equivalents of 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-tri-
azine (pdpt) in methanol at 50 C in the presence of
KPF6 to form the cationic arene ruthenium complexes
[(g6-C6H6)RuCl(pdpt)]
+ (1), [(g6-C6H5Me)RuCl(pdpt)]
+ (2),
[(g6-p-PriC6H4Me)RuCl(pdpt)]
+ (3) and [(g6-C6Me6)RuCl-
(pdpt)]+ (4), which are isolated as their hexaﬂuorophos-
phate salts (Scheme 1). The hexaﬂuorophosphate salts of
complexes 1–4 are orange–brown, non-hygroscopic, air-
stable solids. They are sparingly soluble in methanol, chlo-
roform and water, but well soluble in dichloromethane,
acetone and acetonitrile. All compounds have been charac-
terised on the basis of elemental analysis, 1H NMR, IR,
UV–Vis and mass spectroscopy.of cations 1–4.
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Fig. 2. UV–Vis absorption data of 1–4 in acetonitrile at 298 K.
Fig. 3. Molecular structure of 1 at 50% probability level with hydrogen atoms, benzene molecules and hexaﬂuorophosphate anion have been omitted for
clarity.
4In the mass spectra they give rise to the correspondin
[M]+ molecular peaks m/z at 525, 539, 581 and 609, respec
tively. The 1H NMR spectra of 1–4 exhibit, other than th
signals corresponding to the g6-aromatic ligand, a charac
teristic set of fourteen signals for the diastereotopic proton
of the pdpt ligand. The ruthenium atom is stereogenic du
to the coordination of four diﬀerent ligator atoms. Upo
coordination to the ruthenium atom, the aromatic protonof the pdpt ligand are shifted downﬁeld, especially the H
of the coordinated pyridyl group which is observed a
d > 9.0 ppm, while the Hd is observed at only 8.7 ppm
Accordingly, the aromatic protons of the phenyl group
are observed as multiplet at d  7.45 and 7.75 ppm. Th
1H NMR spectrum of 3 exhibits two doublets for the dia
stereotopic methyl protons of the isopropyl group. Like
wise, the diastereotopic CH protons of the p-cymen
Fig. 4. Molecular structure of 2 at 50% probability level with hydrogen atoms, acetonitrile molecules and hexaﬂuorophosphate anion have been omitted
for clarity.
Table 2
Selected bond lengths (A˚) and angles () for [1][PF6]  (C6H6)2.5 and
[2][PF6]  (CH3CN)2
[1][PF6] [2][PF6]
Interatomic distances
Ru1–N1 2.052(3) 2.054(10)
Ru1–N2 2.087(3) 2.091(10)
Ru1–Cl1 2.387(1) 2.391(3)
Ru1–centroid (arene) 1.681 1.684
C1–C2 1.469(5) 1.464(15)
N1–N3 1.344(4) 1.349(13)
Angles
N1–Ru1–N2 76.5(1) 76.3(4)
N1–Ru1–Cl1 86.38(9) 84.4(3)
N2–Ru1–Cl1 84.79(9) 86.6(3)
Ru1–N1–C1 118.3(2) 118.7(7)
Ru1–N1–N3 121.8(2) 121.1(7)
Ru1–N2–C2 116.9(2) 116.3(7)
5ligand give rise to four doublets observed between d = 5.8–
6.1 ppm. A septet at d = 2.89 ppm is observed for the CH
proton of the isopropyl group. Similarly, the aromatic pro-
tons of the toluene ligand in 2 give rise to ﬁve multiplets
observed between d = 5.79–6.18 ppm and a singlet at
d = 2.17 ppm for the methyl group.
The UV–Vis data of complexes 1–4 have been recorded
in acetonitrile, see Fig. 2. The electronic spectra display a
low energy absorption band in the visible region at
440 nm and an intense band at 300 nm. The low inten-
sity band at 440 nm is assigned to the metal-to-ligand
charge transfer transition (MLCT), while the high-energy
band at 300 nm is assigned to intra-ligand p–p* transi-
tions [11].
The molecular structures of [(g6-C6H6)RuCl(pdpt)]
+ (1)
and [(g6-C6H5Me)RuCl(pdpt)]
+ (2) have been established
by single-crystal X-ray structure analysis of their hexa-
ﬂuorophosphate salts. The complexes show typical piano-
stool geometry with the metal centre coordinated by the
arene ligand, a terminal chloride and the chelating pdpt
ligand. The molecular structures of [1][PF6] and [2][PF6]
are shown in Figs. 3 and 4, respectively, and a series of
selected geometrical parameters are presented in
Table 2.
In the mononuclear complexes 1 and 2, the metal centres
are stereogenic. However, since none of the ligands con-
tains chiral information, they are both obtained as a race-
mic mixture and crystallised in the centrosymmetric space
group P 21/n. The Ru–N bond distances 2.05 and 2.09 A˚
in 1 and 2 are comparable to those in [(g6-p-PriC6H4Me)R-
uCl(2,3-bis(2-pyridyl)pyrazine)][BF4] [12], [(g
6-p-PriC6H4-Me)RuCl(2,3-bis(a-pyridyl)quinoxaline)][PF6] [13], [(g
6-
C6H6)RuCl(dpqMe2)][PF6] (dpqMe2 = 6,7-dimethyl-2,3-
di(pyridine-2-yl)quinoxaline) and [(g6-p-PriC6H4Me)RuCl-
(dpqMe2)][PF6] [14]. Accordingly, there is no signiﬁcant
diﬀerence in the Ru–Cl bond lengths in 1 and 2 [2.387(1)
and 2.391(3) A˚] and reported values [12–14]. The N(1)–
Ru(1)–N(2) bond angles [76.5(1) in 1; 76.3(4) in 2] are sim-
ilar to those of complexes [(g6-p-PriC6H4Me)RuCl(2,3-
bis(2-pyridyl)pyrazine)]+ [N(1)–Ru(1)–N(2) = 76.5(2)]
[12], [(g6-p-PriC6H4Me)RuCl(2,3-bis(a-pyridyl)quinoxa-
line)]+ [N(1)–Ru(1)–N(2) = 76.2(2)] [13], [(g6-C6H6)
RuCl(dpqMe2)][PF6] [N(1)–Ru(1)–N(2) = 76.04(15)] and
–l-
-
r
l,
is
-
6[(g6-p-PriC6H4Me)RuCl(dpqMe2)][PF6] [N(1)–Ru(1)
N(2) = 76.33(10)] [14].
In the presence of benzene, compound [1][PF6] crysta
lises with two and a half molecules of benzene per asymFig. 5. Crystal packin
Fig. 6. Network of 2 showing the inmetric unit, thus giving rise to multiple intermolecula
interactions between the diﬀerent components of the cel
see Fig. 5. Among these intermolecular interactions, it
noteworthy to mention the edge-to-face p-stacking interg of [1][PF6]  (C6H6)2.5.
termolecular p-stacking interactions.
Fig. 7. Interactions involving the hexaﬂuorophosphate anion in
[2][PF6]  (CH3CN)2.
7actions between the centrosymmetric benzene molecule
and the pdpt ligand of two molecules of 1; the C-cen-
troid separation is 3.67 A˚ [H-centroid = 2.85 A˚] with a
C–H  centroid angle of 147.4. Moreover, the hexa-
ﬂuorophosphate anion interacts with neighbouring com-
plexes of 1 and solvent molecules through C–H  F
contacts: the C  F distances ranges from 3.22 to
3.50 A˚ and the C–H  F angles ranging from 126.5 to
163.8.
In the crystal packing of [2][PF6]  (CH3CN)2, the mole-
cules of 2 form a network through p-stacking interactions
between parallel aromatic rings of adjacent complexes,
see Fig. 6. There are two types of p–p stacking interactions
involve in the multimeric system, a face-to-face and an
edge-to-face types. The centroid-centroid separation of
the slipped parallel interacting system (face-to-face) is
3.81 A˚, while the edge-to-face C-centroid separation is
3.29 A˚ [H-centroid = 2.58 A˚, C–H  centroid angle =
133.6]. The distance observed between the p–p interacting
systems is in accordance with the theoretical value calcu-
lated for this stacking mode [15].
In addition to the p-stacking interactions, in the crystal
packing of [2][PF6]  (CH3CN)2, the hexaﬂuorophosphate
anion sits on top of the cationic complex and interacts with
adjacent acetonitrile molecules, see Fig. 7. The distance
between the centroid of the 1,2,4-triazine ring of the pdpt
ligand and the ﬂuorine atom is 3.00 A˚. The hexaﬂuoro-
phosphate anion interacts as well with neighbouring sol-
vent molecules through C–H  F contacts: the C  F
distances being 3.72 and 3.82 A˚ with C–H  F angles of
167.6 and 116.5, respectively.
In conclusion, we have synthesised and characterised
four arene ruthenium complexes with the polypyridyl che-late ligand, 5,6-diphenyl-3-(pyridine-2-yl)-1,2,4-tri-
azine(pdpt). As shown by the X-ray structure analysis of
complexes 1 and 2, after coordination to the ruthenium
atom, the pdpt ligand possesses a free pyridyl function
for intermolecular interactions. The biological activity
and DNA interactions of these complexes are under
investigation.
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Appendix A. Supplementary material
CCDC 657156 and 647515 contain the supplementary
crystallographic data for [1][PF6]  (C6H6)2.5 and
[2][PF6]  (CH3CN)2. These data can be obtained free of
charge from The Cambridge Crystallographic Data Centre
via www.ccdc.cam.ac.uk/data_request/cif. Supplementary
data associated with this article can be found, in the online
version, at doi:10.1016/j.ica.2007.11.007.
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